IP Library › Granted Patent US 12,735,504
Granted Patent B2
US 12,735,504 · App. 17/793,483 · Granted Sep 15, 2026

Anti D-Dimer recombinant antibodies, methods and uses thereof

Inventors: Elizabeth A. Booth (Emeryville, CA); Charles Holz (Emeryville, CA); Tristan Wasley (Emeryville, CA); Virginia Montanini (Sant Cugat del Valles, ES); Jody Berry (Emeryville, CA)
Assignee: F. HOFFMANN-LA ROCHE AG
C07K16/36C07K2317/565C07K2317/92C07K2319/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,735,504
App. No.
17/793,483
Granted
Sep 15, 2026
Kind
B2
Abstract

This application relates to anti-D-Dimer recombinant antibodies that specifically bind to fibrin and fibrinogen degradation products (FDP) such as D-Dimer, fragment DD and fragment D with high binding affinity and do not bind to fragment E and fibrinogen. The present invention also refers to methods and assays for detection of D-Dimer and FDP fragments in samples using said recombinant antibodies.

Claims (20)

1 . An anti-D-dimer recombinant antibody that specifically binds to fibrin degradation products and fibrinogen degradation products, wherein the fibrin degradation products and the fibrinogen degradation products include D-Dimer, fragment DD and fragment D, but the recombinant antibody does not bind to either fragment E and fibrinogen, wherein fragment E is a fibrin degradation product or a fibrinogen degradation product, and wherein the anti-D-dimer recombinant antibody comprises:

a light chain variable region comprising the amino acid sequence of SEQ ID NO: 31 (L-CDR1); the amino acid sequence of SEQ ID NO: 32 (L-CDR2); and the amino acid sequence of SEQ ID NO: 33 (L-CDR3); and

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 34 (H-CDR1); an amino acid sequence selected from the group consisting of SEQ ID NO: 35, SEQ ID NO: 37, and SEQ ID NO: 38 (H-CDR2); and the amino acid sequence of SEQ ID NO: 36 (H-CDR3).

2 . The recombinant antibody according to claim 1 , wherein said light chain comprises the amino acid sequence of SEQ ID NO: 18.

3 . The recombinant antibody according to claim 1 , wherein said heavy chain comprises the amino acid sequence of SEQ ID NO: 19, or SEQ ID NO: 20, or SEQ ID NO: 21 or SEQ ID NO: 22.

4 . The recombinant antibody according to claim 1 , comprising:

a light chain variable region comprising an amino acid sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or about 99% identical to SEQ ID NO: 18, and

a heavy chain variable region comprising an amino acid sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or about 99% identical to a sequence selected from the group consisting of SEQ ID NOs: 19, 20, 21, and 22.

5 . The recombinant antibody according to claim 1 , comprising:

a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18, and

a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 20, 21, and 22.

6 . The recombinant antibody according to claim 1 , comprising:

a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18, and

a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19 and 20.

7 . The recombinant antibody according to claim 1 , further comprising an affinity tag.

8 . The recombinant antibody according to claim 7 , wherein the amino acid sequence of the affinity tag is selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 24, or SEQ ID NO: 25.

9 . The recombinant antibody according to claim 1 , wherein the light chain of said recombinant antibody comprises the amino acid sequence of SEQ ID NO: 17.

10 . The recombinant antibody according claim 1 , wherein the heavy chain of said recombinant antibody comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO: 16.

11 . The recombinant antibody according to claim 1 , wherein the light chain of said recombinant antibody comprises the amino acid sequence of SEQ ID NO: 17 and the heavy chain of said recombinant antibody comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, or SEQ ID NO:16.

12 . The recombinant antibody according to claim 1 , wherein the recombinant antibody comprises the amino acid sequence of SEQ ID NO: 17 and the amino acid sequence of SEQ ID NO: 12.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2022
From: GRIFOLS DIAGNOSTIC SOLUTIONS INC.
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 060534/0737 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2022
From: BOOTH, ELIZABETH A.; HOLZ, CHARLES; WASLEY, TRISTAN; MONTANINI, VIRGINIA; BERRY, JODY
To: GRIFOLS DIAGNOSTIC SOLUTIONS INC.
Reel/Frame 060682/0816 →
Continuity (2)
Provisional Application 62979253 · Feb 20, 2020
Related Publication 20230082465A1 · Mar 16, 2023
References Cited (63)
US 6180370B1 · Queen · 2001 [cited by examiner]
US 8940489B2 · Doh · 2015 [cited by examiner]
US 10112990B2 · Adolfsson et al. · 2018 [cited by applicant]
US 11159971B2 · AlBanna · 2021 [cited by applicant]
US 20090298100A1 · Doh et al. · 2009 [cited by applicant]
US 20130011869A1 · Nagahama et al. · 2013 [cited by applicant]
US 20160047903A1 · Dussan · 2016 [cited by applicant]
US 20190224339A1 · Paul et al. · 2019 [cited by applicant]
US 20200022462A1 · Lee et al. · 2020 [cited by applicant]
US 20200339682A1 · Kamogawa et al. · 2020 [cited by applicant]
US 20210047389A1 · Kobie et al. · 2021 [cited by applicant]
US 20210070881A1 · Dennis et al. · 2021 [cited by applicant]
US 20220204582A1 · Chaudhary · 2022 [cited by applicant]
EP 0348875A2 · 1990 [cited by applicant]
EP 2554673A1 · 2013 [cited by applicant]
JP 61222175A · 1988 [cited by applicant]
JP 2018531002A · 2018 [cited by applicant]
KR 20200122467A · 2020 [cited by applicant]
WO 2007013709A1 · 2007 [cited by applicant]
WO 2011041518A1 · 2011 [cited by applicant]
WO 2011125875A1 · 2011 [cited by applicant]
WO 2017050722A1 · 2017 [cited by applicant]
WO 2017193096A1 · 2017 [cited by applicant]
WO 2019133512A1 · 2019 [cited by applicant]
WO 2019237350A1 · 2019 [cited by applicant]
WO 2020113054A1 · 2020 [cited by applicant]
WO 2020144697A1 · 2020 [cited by applicant]
WO 2020210665A1 · 2020 [cited by applicant]
WO 2020228806A1 · 2020 [cited by applicant]
WO 2021032078A1 · 2021 [cited by applicant]
Piche-Nicholas, Nicole M., et al. “Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.” MAbs. Vol. 10. No. 1. Taylor & Francis, 2018 (Y… [cited by examiner]
Sela-Culang, Inbal, Vered Kunik, and Yanay Ofran. “The structural basis of antibody-antigen recognition.” Frontiers in immunology 4 (2013): 302 (Year: 2013). [cited by examiner]
Janeway, Charles A. “Immunobiology: The Immune System in Health and Disease.” 2001 (Year: 2001). [cited by examiner]
Kipriyanov, Sergey M., and Fabrice Le Gall. “Generation and production of engineered antibodies.” Molecular biotechnology 26.1 ( 2004): 39-60. (Year: 2004). [cited by examiner]
Rylatt, D.B. et al. “An Immunoassay for Human D Dimer Using Monoclonal Antibodies” Pergamon Press Ltd., 1983, pp. 767-778, vol. 31. [cited by applicant]
Soe, Gilbu et al. “ Analysis of Plasmin-digests of Cross-linked Fibrin Utilizing an Antibody Recognizing the Amino-Terminal Conformation of Fragment D” Japanese Journal of Thrombosis and Hemostasis, 1994, pp. 105-113, v… [cited by applicant]
Holvoet, P. et al. “Binding Properties of Monoclonal Antibodies against Human Fragment of D-Dimer of Cross-Linked Fibrin to Human Plasma Clots in an In Vivo Model of Rabbits” Thrombosis and Haemostasis, 1989, pp. 307-31… [cited by applicant]
Torok-Nagy, Beata et al. “Generation and characterization of D-dimer specific monoclonal antibodies for use in latex agglutination test” Plos One, 2019, pp. 1-10, vol. 14. [cited by applicant]
Castillo et al., “Hybridoma stability”, Dev. Biol. Stand. 83, 55-64, 1994, Abstract Only. [cited by applicant]
International Search Report pertaining to Application No. PCT/IB2021/051438 dated May 4, 2021. [cited by applicant]
Holvoet et al., “Binding Properties of Monoclonal Antibodies against Human Fragment D-Dimer of Cross-Linked Fibrin to Human Plasma Clots in an In Vivo Model in Rabbits”, Thrombosis and Haemostasis, vol. 61, No. 2, pp. 3… [cited by applicant]
Weitz et al., “A Test in Context: D-Dimer”, Journal of the Americal College of Cardiology, vol. 70, No. 19, 2017. [cited by applicant]
Adam et al., “D-dimer antigen: current concepts and future prospects”, Blood, vol. 113, No. 13, pp. 2878-2887, Mar. 26, 2009. [cited by applicant]
Chothia et al., “Conformations of immunoglobulin hypervariable regions”, Nature, vol. 342, pp. 877-883 , Dec. 21/28, 1989. [cited by applicant]
Coco-Martin et al., “Instability of Hybridoma Cell Line in a Homogeneous Continuous Perfusion Culture System”, Hybridoma, vol. 11, No. 5, Nov. 5, 1992. [cited by applicant]
Doh et al., “Novel monoclonal antibody that recognizes new neoantigenic determinant of D-dimer”, Thrombosis Research, vol. 118, pp. 353-360, 2006. [cited by applicant]
Dong et al., “Generation of a Monoclonal Antibody against D-Dimer Using HTS-Based LiCA”, SLAS Disclovery, vol. 25, No. 3, pp. 310-319, 2020. [cited by applicant]
Goodacre et al., “Variation in the diagnostic performance of D-dimer for suspected deep vein thrombosis”, Q J Med, vol. 98, pp. 513-527, Jun. 13, 2005. [cited by applicant]
Gupta et al., “Glycosylation control technologies for recombinant therapeutic proteins”, Applied Microbiology and Biotechnology, vol. 102, p. 10457-10468, 2018. [cited by applicant]
Holvoet et al., “A Monoclonal Antibody Preventing Binding of Tissue-Type Plasminogen Activator to Fibrin: Useful to Monitor Fibrinogen Breakdown During t-PA Infusion”, Blood, vol. 67, No. 5, pp. 1482-1487, May 1986. [cited by applicant]
Kogan et al., “Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products”, Blood Coagulation & Fibrinolysis, vol. 27, No. 5, Dec. 11, 2015. [cited by applicant]
Lefranc et al., “IMGT, the international ImMunoGeneTics information system”, Nucleic Acids Research, vol. 33, 5 ogs., 2005. [cited by applicant]
Lippi et al., “Interference from heterophilic antibodies in D-dimer assessment. A case report”, Blood Coagulation and Fibrinolysis, vol. 25, No. 3, pp. 277-279, 2014. [cited by applicant]
Maccallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography”, J. Mol. Bio., vol. 262, pp. 72-745, 1996. [cited by applicant]
Makabe et al., “Thermodynamic Consequences of Mutations in Vernier Zone Residues of a Humanized Anti-human Epidermal Growth Factor Receptor Murine Antibody, 528”, The Journal of Biological Chemistry, vol. 283, No. 2, pp… [cited by applicant]
Morris et al., “Improved imaging of deep venous thrombi during anticoagulation using radiolabelled anti-D-dimer antibodies”, Nuclear Medicine, vol. 25, No. 9, pp. 917-922, 2004. [cited by applicant]
Pfitzner et al., “Fabin Detected in Plasma of Patients with Disseminated Intravascular Coagulation by Fibrin-specific Antibodies Consists Primarily of High Molecular Weight Factor XIIIa-crosslinked and Plasmin-modified … [cited by applicant]
Riley et al., “Widely Used Types and Clinical Applications of D-Dimer Assay”, Laboratory Medicine, Vo91. 47, No. 2, bp. 90-102, Mar. 25, 2016. [cited by applicant]
Robier et al., “False-positive D-dimer result in a latex-enhanced immunoassay caused by interfering human antimouse antibodies”, Clin Chem Lab Med, vol. 52, No. 11, pp. e253-e255, 2014. [cited by applicant]
Tasic et al., “Biosensing of D-dimer, making the transition from the central hospital laboratory to bedside determination”, Talanta, vol. 207, 8 p. 2020. [cited by applicant]
Thachil et al., “D-Dimer Testing: Laboratory Aspects and Current Issues”, Hemostasis and Thrombosis: Methods and Protocols, Methods in Molecular Biology, vol. 1646, pp. 91-104, 2017. [cited by applicant]
Dan, Zhaokui, et al. Construction and Expression of D-dimer and GPllb/Illa single-chain bispecific antibody, Experimental and Therapeutic Medicine May 16, 2013, 552-556, 6. [cited by applicant]
Communication pursuant to Article 94(3) EPC corresponding to European Patent Application No. 21708752.7, dated 1 Mar. 9, 2026, 11 pages, European Patent Office (EPO). . [cited by applicant]